Skip to content
Menu

TD Cowen Maintains Buy on Milestone Pharmaceuticals, Lowers Price Target to $5

Benzinga Newsdesk 1 day ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

TD Cowen analyst Ritu Baral maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and lowers the price target from $8 to $5.

TD Cowen analyst Ritu Baral maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and lowers the price target from $8 to $5.

Read at benzinga.com